Intradermally Administered Yellow Fever Vaccine at Reduced Dose Induces a Protective Immune Response: A Randomized Controlled Non-inferiority Trial

Anna H.E. Roukens1, Ann C.T.M. Vossen2, Peter J. Bredenbeek3, Jaap T. van Dissel1, Leo G. Visser1

PLoS ONE. 2008; 3:e1993

1 Dept. of Infectious Diseases, Leiden University Medical Centre, the Netherlands
2 Dept. of Medical Microbiology, Leiden University Medical Centre, the Netherlands
3 Dept. of Virology, Leiden University Medical Centre, the Netherlands
Abstract

Background
Implementation of yellow fever vaccination is currently hampered by limited supply of vaccine. An alternative route of administration with reduced amounts of vaccine but without loss of vaccine efficacy would boost vaccination programmes.

Methods
A randomised, controlled, non-inferiority trial was conducted in a Dutch university centre between August 2005 and February 2007. A total of 155 primary vaccinated and 20 previously vaccinated volunteers participated. Participants were randomly assigned in a 1:1 ratio to receive intradermal (i.d.) vaccination with live attenuated yellow fever 17D vaccine at a reduced dose (1/5th; 0.1 mL) or the conventional subcutaneous (s.c.) vaccination (0.5 mL). Antibody neutralisation titres were determined at 2, 4 and 8 weeks and 1 year after vaccination by counting the reduction in virus-induced plaques in the presence of serial serum dilutions. Adverse events were documented in a 3-week dairy. Viraemia was measured 5 days after vaccination.

Results
From 2 weeks up to one year after vaccination, the maximum serum-dilution at which 80% of the virus plaques were neutralised, which indicates protection against yellow fever, did not differ between those given a reduced i.d. dose or standard s.c. dose of vaccine. In all cases the WHO standard of seroprotection (i.e. 80% virus neutralisation) was reached (in 77/77 and 78/78, respectively). Similar results were found in the previously vaccinated individuals. Viraemia was detected in half of the primary vaccinated participants, which was not predictive of serological response. In revaccinees no viraemia was detected.

Conclusions
Intradermal administration of one fifth of the amount of yellow fever vaccine administered subcutaneously results in protective seroimmunity in all volunteers. Albeit this vaccination route should enable vaccination of five-times as many individuals at risk for disease, these results should now be confirmed in field studies in areas with potential yellow fever virus transmission to change vaccination policy.
Introduction

Yellow fever is a re-emerging viral hemorrhagic febrile illness in tropical and sub-tropical areas of Africa and remains a major health threat in South-America. It is estimated to affect 200,000 individuals annually of whom approximately 30,000 die worldwide [1]. The virus is transmitted by infected *Aedes* mosquitoes, and may cause a wide spectrum of disease, from mild symptoms to severe illness accompanied by fever, hepatic and myocardial injury, renal failure, hemorrhage, and even death. There is no curative treatment for yellow fever, making vector control and vaccination essential ingredients in the prevention of yellow fever morbidity and mortality.

Although this flavivirus has never emerged in Asia, the Asian continent is considered vulnerable to future introduction of the virus, because of the presence of a large susceptible human population, the presence of the urban vector and increasing international travel [2]. Also Western countries may be at risk: for instance, in the Netherlands, the *Aedes albopictus* mosquito was introduced via imported bamboo from China, and its capability of transmission of flaviviruses is currently under investigation.

Thus, there is a potential risk for large epidemics of urban yellow fever now that migration of people from rural areas may introduce the virus into areas of high human population density, such as large African and South-American cities. During yellow fever epidemics in non-immune populations, case-fatality rates may be as high as 50% [3]. In case of simultaneous outbreaks in megacities the current emergency stockpile of yellow fever vaccine of 6 million doses will not be sufficient to protect the large populations from the disease [4].

Yellow fever vaccination is the single most important and effective means to prevent the occurrence of yellow fever, and carries a low risk of serious adverse events. The live-attenuated 17D vaccine provides protective immunity within one to two weeks in 95% of those vaccinated [5]. The World Health Organization (WHO) therefore strongly recommends to include yellow fever vaccination in at-risk countries, as part of the routine childhood immunisation program. However, hampered by a limited vaccine supply, this recommendation has not yet been acted upon as epidemic emergencies have priority. Besides mass immunisation campaigns in response to epidemic outbreaks and planned routine childhood immunisation programmes, yellow fever vaccination is used for preventive immunisation of travellers to endemic regions [6]. Therefore, to circumvent the consequence of current shortage of vaccine supplies,
there is an urgent need to find alternatives for the current standard of yellow fever vaccination, i.e., the subcutaneous administration of 0·5 mL 17D vaccine.

In general, the route of administration of a particular vaccine, e.g., intramuscular, subcutaneous or intradermal, appears to have been reached at arbitrary historical grounds. For the yellow fever vaccine, subcutaneous administration of 0·5 mL followed the initial human trials in which yellow fever 17D (YF-17D) vaccines were first put to extensive use. However, for some vaccines already, for instance rabies, hepatitis B and influenza vaccines, the classical subcutaneous or intramuscular routes have been challenged by the apparent efficacy of intradermal administration using appreciably smaller amounts of vaccine [7-10]. The safety and efficacy of this route of administration has not been addressed for the yellow fever vaccine. Interestingly, already in 1943, at the dawn of yellow fever vaccine development, Fox and colleagues observed an immune response after intradermal administration of the YF-17D vaccine [11]. However, the population investigated was small and the method used to assess antibody responses is irreconcilable with current definitions of seroprotection formulated by the WHO. Furthermore, scarification experiments with yellow fever vaccine conducted in the 1950s revealed a lower response rate when compared to subcutaneous inoculation [12,13].

In this study we investigate the efficacy of intradermal inoculation of yellow fever vaccine at one fifth the amount given subcutaneously, as a potential strategy to reduce costs and increase vaccine coverage in areas with limited amounts of vaccine available for mass vaccination as well as for travellers to these areas. Furthermore, to elucidate requirements for the induction of an effective immune response to yellow fever vaccination we assessed antibody responses in relation to post-vaccination viraemia in both primary and revaccinated individuals.

**Methods**

**Objectives**

This study was conducted to determine whether reduced dose i.d. yellow fever vaccination (1/5th; 0·1 mL) would be as efficacious and safe as the conventional s.c. vaccination (0·5 mL). Efficacy of vaccination was measured by virus neutralisation plaque reduction assay.
Study design and Participants
Healthy volunteers of 18 years and older were eligible for inclusion. We excluded volunteers with a compromised immunity due to underlying illness or immunosuppressive medication, pregnant volunteers and those with chicken egg allergy. The study was carried out between August 2005 and February 2007. Subjects were randomly assigned by the investigator (AHR) to either receive intradermal (i.d.) (experimental vaccination group) or subcutaneous (s.c.) (conventional vaccination group) yellow fever vaccination. Randomization was performed with the use of sealed envelopes containing the vaccination code balanced through permuted blocks of 10 each. Vaccinations were administered at the travel clinic of the LUMC by the investigators who were trained in both methods of vaccine administration.
In the experimental vaccination group, participants received 0.1 mL YF-17D vaccine intradermally on the dorsal side of the right forearm. The syringe which was used for i.d. administration is identical to the syringe used for administration of tuberculin in the Mantoux test. The quality of the i.d. injection was defined by the diameter of the arisen cutaneous wheal (adapted from the tuberculin skin test) [14], with 6 mm being the lowest acceptable diameter. The conventional vaccination group received 0.5 ml YF-17D vaccine subcutaneously in the right upper deltoid region.

17D Yellow Fever Vaccine
The live, attenuated, 17D vaccine used in this study was manufactured on embryonated chicken eggs according to WHO regulations and stored according to manufacturer’s guidelines. All administered vaccines originated from the same vaccine lot (Stamaril, Lot no Y5597, Sanofi Pasteur, France). A single vaccination dose of 0.5 ml contained approximately 3.5 x 10^4 plaque forming units (PFU), measured in two randomly selected vials. Multiple dosages (maximally 4) were obtained from one vial for i.d. vaccination. After reconstitution, vials were stored at 4°C and discarded after maximally 4 hours.

Data collection
At the time of inclusion, data on demographic and clinical characteristics of the participants were obtained, including information on possible flavivirus exposure (defined as travel to a flavivirus endemic country) in the 5 years prior to entering the study and previous yellow fever vaccination. Blood samples were collected in all (155) primary vaccinated participants before vaccination, and 4 and 8 weeks after vaccination. An additional blood sample was collected 2 weeks after vaccination in 55 primovaccinees (the last 55 consecutive subjects entering the study) to investigate the kinetics of the neutralising antibody response in more detail.
Extra ethylenediamine tetraacetic acid (EDTA) blood samples were collected 5 days after vaccination in the first 24 consecutive primovaccinees entering the study. In 20 previously vaccinated participants blood was drawn before vaccination, and 5 days and 2 weeks after booster vaccination (figure 1). Approximately one year after vaccination, one additional blood sample was taken from all participants who could be contacted (96 participants). A financial compensation was given for every blood sample collection at completion of the study. None of the participants withdrew prematurely.

Participants were asked to document clinical symptoms (local and systemic) after vaccination in a three-week diary. Solicited symptoms were; erythema, pain and swelling at the site of injection, fever and myalgia. Severity of adverse events was documented as – (absent), +/− (mild), + (moderate) and ++ (severe).

**Constant virus – varying serum dilution Plaque Reduction Neutralisation Test (PRNT)**

The tests were carried out in 6-well plates (Corning Inc., USA) using a slightly modified technique described originally by De Madrid and Porterfield [15]. Briefly, approximately 6 x 10^5 Vero cells/mL were seeded per well in 6–well plates and cultured to obtain a confluent monolayer. Sera were complement inactivated at 56°C for 1 hour. Prevacccination sera were tested in 1:16 dilution, to which 100 PFU of 17D-YF were added. Postvaccination sera were tested in two-fold dilutions starting from 1:16 to 1:512. 100 PFU YF-17D virus were added to each serum dilution. All test sera were assayed in duplicate. After 1 hour incubation on ice, the mixtures of virus and serum were added to the Vero cell monolayers and incubated for 1 hour at 37°C. An overlay of 2 x DMEM and 2% agarose was added. After 5 days of incubation at 37°C, the overlay was discarded and cell monolayers were stained with crystal violet. Plaques were counted by eye. Virus neutralisation (VN) was calculated for each serum dilution (i) with the following formula: VN(i) = 100 x (number of PFU in diluted postvaccination serum / number of PFU in pre-vaccination serum (in a 1:16 dilution)). For comparison of i.d. and s.c. vaccination, serum dilution at which log_{10} neutralisation index 0.7 (80% VN) occurred was taken as endpoint, as this corresponds to the generally accepted definition of protection [16].

**Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)**

RT–PCR of YF–17D was performed at the department of Virology of the Erasmus Medical Centre according to Nijhuis and colleagues [17]. Briefly, viral RNA was isolated and reverse transcribed (Taqman Reverse Transcription Reagents, Applied
Biosystems International). cDNA synthesis was performed in a J Mini Gradient Thermal Cycler (BioRad, Netherlands) for real-time PCR, the following YF specific primers and probe were used [18]:

- **YFV-1 (forward)**: AATCGAGTTGCTAGGCAATAAAC
- **YFV-2 (reverse)**: TCCCTGAGCTTTACCAGA
- **YFV-P (probe)**: FAM-ATCGTTGAGCGATTAGCAG-BHQ

with FAM (6-carboxyfluorescein) as 5'-reporter dye and BHQ (Black Hole Quencher) as the 3'-quencher dye. Real-time PCR was monitored on ABI Prism 7500 Seq. Detection System (Applied Biosystems International). Cycle threshold (Ct) values were used to compare viraemia in i.d. and s.c. groups quantitatively.

**Ethics**

The protocol and consent forms were approved by the Medical Ethical Committee of the Leiden University Medical Centre (LUMC), the Netherlands (ISRCTN46326316). Written informed consent was obtained from each participant.

**Statistical methods**

Power calculations for primovaccinees were based on a one-sided non-inferiority according to Armitage P., et al. [19], formula 18.5, with a maximally acceptable difference ($\delta$) of 0.04 between the experimental and conventional vaccination group, $\alpha$ of 0.05, $\beta$ of 0.2 and a $\pi$ (overall probability of positive response) of 0.99 [5], which makes $\sigma^2 = 0.0099$. The number of participants needed to confirm non-inferiority of low dose i.d. vaccination under these assumed conditions are 77 per group. For the antibody response in previously vaccinated individuals receiving a booster vaccination, basic descriptive statistics are used. It was anticipated that the small number in this subgroup would not allow a definite conclusion concerning non-inferiority and no power calculation was performed. Twenty previously vaccinated persons were included to monitor possible trends in interference of neutralising antibodies in yellow fever vaccination. Paired t-test was performed to calculate their increase in neutralisation after booster vaccination and linear regression was used to calculate influence of circulating antibodies on booster vaccination. Neutralising capacity of sera after i.d. and s.c. vaccination were compared with Student’s t-test. Where appropriate, Chi-square tests were used, and Wilcoxon’s test for non-parametrical distributed numerical data. Statistical analysis was performed using a computer-assisted software package (SPSS version 12.0, SPSS Inc., Chicago, IL).
Results

Study population
We enrolled 175 volunteers from August 2005 to February 2007 (figure 1). Baseline characteristics of the study population are given in table 1. Concerning the accuracy of i.d. vaccine delivery, the mean diameter of the cutaneous wheal measured after vaccination was 8 mm (range 6-10 mm), indicating that all (N=87) i.d. vaccination wheals met the minimal requirement for acceptable size.

Intradermal yellow fever vaccination

Figure 1  Flow chart of study participants

175 Included

155 Primovaccinees

28 serology
2 wks PV
77 serology
4 and 8 wks PV
37 serology
± 1 yr PV
13 RT-PCR
5 days PV
77 adverse event
diary 3 wks PV

78 subcutaneous

27 serology
2 wks PV
78 serology
4 and 8 wks PV
44 serology
± 1 yr PV
11 RT-PCR
5 days PV
78 adverse event
diary 3 wks PV

20 Revaccinees

10 intradermal

9 serology
2 wks PV
8 serology
± 1 yr PV
10 RT-PCR
5 days PV
10 adverse event
diary 3 wks PV

10 subcutaneous

10 serology
2 wks PV
7 serology
± 1 yr PV
10 RT-PCR
5 days PV
10 adverse event
diary 3 wks PV

Included study participants from August 2005 until February 2007. PV = post vaccination. RT–PCR = Reverse transcriptase polymerase chain reaction. Wks = weeks and yr = year.
Four weeks after vaccination, 80% virus neutralisation (VN) at the least diluted serum (dilution of 1:16) was achieved by 77 of 77 of the intradermally and by 78 of 78 of the subcutaneously vaccinated primovaccinees. The percentage of VN in both study groups was linearly correlated to serum dilution at all time points measured (data not shown).

Ninety percent neutralisation was achieved by 70 of 77 (91%) and by 69 of 78 (89%), respectively. Plotting of neutralisation indices against serum dilution showed similar kinetics of i.d. and s.c. vaccination at all measured time points (data not shown). This allowed us to compare the serum dilution at which 80% of yellow fever was neutralised, which is similar in both groups at all time points measured (figure 2).

No difference in percentage of virus neutralisation was measured in either (i.d. or s.c.) group between male and female participants, nor between recent travel to flavivirus endemic countries or not (data not shown).

Neutralising capacity of 1:16 diluted prevaccination serum of previously vaccinated participants ranged from 2% to 97% reflecting the wide range of years since their last YF vaccination (0.5 to 18 years). The mean percentage of VN by the least diluted serum before vaccination in the i.d. group was 77% (range 51%–97%) and in the s.c. group was 74% (range 2%–97%). All revaccinees reached protective neutralisation immunity 2 weeks (19/19) and 1 year (15/15) after vaccination.

Both the i.d. and the s.c. group of revaccinated participants showed a significant rise in VN after booster vaccination. The mean increase in percentage of neutralisation by serum (dilution 1:16) before and 2 weeks after vaccination in the i.d. vaccinated participants was 18% (95% CI; 8%–28%) and 20% (95% CI; 4%–36%) in the s.c. group.

### Table 1

Comparability of intradermally and subcutaneously vaccinated groups

| Participants | Vaccine administration | Intradermal | Subcutaneous | p-value |
|--------------|------------------------|-------------|--------------|---------|
| Primovaccinees | N Female (%) | 56 (73) | 65 (83) | 0.1 |
| Mean age (range) | 27 (18-61) | 25 (19-70) | 0.2 |
| Flavivirus\| N yes (%) | 33 (43) | 26 (33) | 0.3 |
| Revaccinees | N Female (%) | 7 (70) | 8 (80) | - |
| Mean age (range) | 30 (20-50) | 34 (21-48) | 0.4 |

Age and gender distribution in primary (77 i.d., 78 s.c.) and booster (10 i.d., 10 s.c.) vaccinated populations. YF-17D = yellow fever vaccine virus. Flavivirus = possible flavivirus encounter in past five years defined as travelled to flavivirus endemic destination.

**Vaccine efficacy**

Four weeks after vaccination, 80% virus neutralisation (VN) at the least diluted serum (dilution of 1:16) was achieved by 77 of 77 of the intradermally and by 78 of 78 of the subcutaneously vaccinated primovaccinees. The percentage of VN in both study groups was linearly correlated to serum dilution at all time points measured (data not shown).

Ninety percent neutralisation was achieved by 70 of 77 (91%) and by 69 of 78 (89%), respectively. Plotting of neutralisation indices against serum dilution showed similar kinetics of i.d. and s.c. vaccination at all measured time points (data not shown). This allowed us to compare the serum dilution at which 80% of yellow fever was neutralised, which is similar in both groups at all time points measured (figure 2).

No difference in percentage of virus neutralisation was measured in either (i.d. or s.c.) group between male and female participants, nor between recent travel to flavivirus endemic countries or not (data not shown).

Neutralising capacity of 1:16 diluted prevaccination serum of previously vaccinated participants ranged from 2% to 97% reflecting the wide range of years since their last YF vaccination (0.5 to 18 years). The mean percentage of VN by the least diluted serum before vaccination in the i.d. group was 77% (range 51%–97%) and in the s.c. group was 74% (range 2%–97%). All revaccinees reached protective neutralisation immunity 2 weeks (19/19) and 1 year (15/15) after vaccination.

Both the i.d. and the s.c. group of revaccinated participants showed a significant rise in VN after booster vaccination. The mean increase in percentage of neutralisation by serum (dilution 1:16) before and 2 weeks after vaccination in the i.d. vaccinated participants was 18% (95% CI; 8%–28%) and 20% (95% CI; 4%–36%) in the s.c. group.
Intradermal yellow fever vaccination

Figure 2  Protective virus neutralisation after intradermal or subcutaneous vaccination against yellow fever

Comparison of reciprocal serum dilutions at which 80% of yellow fever virus is neutralised in constant virus – varying serum dilution test after intradermal and subcutaneous YF vaccination in primary vaccinated participants (n=155). Bars represent 95% Confidence Intervals (CI). Virus neutralising capacity of serum in both groups was performed at similar time points but indicators are juxtaposed for visual enhancement. VN = virus neutralisation.

(data not shown). To investigate the influence of prevaccination neutralising antibody titre on postvaccination VN, pre- and post vaccination serum dilutions at which 80% VN occurred were plotted (figure 3). In linear regression analysis, an increase in post-vaccination VN correlated significantly with a higher prevaccination antibody titre (coefficient 0.54, p=0.02). Thus, the presence of circulating neutralising antibodies in this population did not inhibit a booster response.

Viraemia was measured by RT-PCR 5 days after vaccination in 24 primovaccinees and all revaccinees (N=20). In the latter no YF-17D RNA was detected in the blood. The percentage of primary vaccinated subjects positive for YF virus detection was comparable in the i.d. (7 of 13, 54%) and s.c. (5 of 11, 45%) group, as were the mean Cycle threshold (Ct) values (35.86 cycles and 37.52 cycles, respectively).
No difference was measured in the serum dilution at which 80% VN occurred 4 weeks after vaccination between those with and those without viraemia, irrespective of the route of vaccine administration (figure 4).

Vaccine safety
Participants reported duration and severity of adverse events after yellow fever vaccination in a 3–week diary. In primary vaccinated participants i.d. vaccination evoked redness and swelling at the site of inoculation more frequently and for a significantly longer period than after s.c. vaccination ($p<0.001$). Itching at the site of injection was also reported more by i.d. vaccinated primovaccinees ($p=0.02$). The s.c. vaccinated primovaccinees reported significantly longer pain at the site of injection.

**Figure 3** Pre- and post vaccination virus neutralising capacity of serum of previously vaccinated participants

Pre- and postvaccination (2 weeks) serum dilutions at which 80% VN occurred in previously vaccinated participants. When 80% VN was not reached by the least diluted serum (1:16), samples were defined as $<16$ (reciprocal serum dilution). VN = Virus neutralisation.
(p=0·03), and more s.c. primary vaccinated participants reported myalgia (p<0·01) (table 2). In previously vaccinated participants, a similar trend of adverse events was monitored except for myalgia.

The severity of adverse events due to vaccination, which was reported on a 4-level scale (−, +/-, +, ++), did not reveal a difference in experienced discomfort (both local and systemic) between the i.d. and s.c. group. Of the reported adverse events, 2/3rd was experienced as mild (+/-) and 1/3rd as moderate (+). No i.d. vaccinated and 3 s.c. participants rated their events as severe (++).
### Discussion

Intradermal administration of 1/5\(^{th}\) of the conventional yellow fever vaccine dose was non-inferior to standard subcutaneous vaccination of the full dose as far as protective immune response and safety is concerned: at 2, 4 and 8 weeks after administration, as well as one year later, the titres of yellow fever-neutralising antibodies were identical in individuals being primary vaccinated intradermally or subcutaneously. Both i.d. and s.c. administration of the vaccine resulted in protective seroimmunity in all subjects.

---

#### Table 2  Solicited adverse events after primary and booster YF-17D vaccination

| Adverse event | Primary vaccination (\(N=155\)) | Booster vaccination (\(N=20\)) |
|---------------|----------------------------------|-------------------------------|
|               | Intradermal | Subcutaneous | Intradermal | Subcutaneous |
|               | Intradermal | Subcutaneous | Intradermal | Subcutaneous |
| Local Erythema| N yes (%) | 63 (82) | 25 (32) | 6 (60) | 1 (10) |
|               | Mean N days (s.e.m.) | 4.3 (±0.5) | 1.1 (±0.2) | 3.2 (±1.0) | 1.0 (±0.9) |
| Local Swelling| N yes (%) | 52 (68) | 9 (12) | 6 (60) | 0 (0) |
|               | Mean N days (s.e.m.) | 2.6 (±0.4) | 0.3 (±0.1) | 2.6 (±0.9) | - |
| Local Pain    | N yes (%) | 6 (8) | 15 (19) | 2 (20) | 0 (0) |
|               | Mean N days (s.e.m.) | 0.1 (±0.06) | 0.6 (±0.2) | 0.2 (±0.1) | - |
| Local Severity| N +/- (mild) | 39 | 15 | 3 | - |
|               | N + (moderate) | 24 | 9 | 2 | 2 |
|               | N ++ (severe) | - | 1 | - | - |
| Systemic Myalgia| N yes (%) | 12 (16) | 27 (22) | 1 (10) | 1 (10) |
|               | Mean N days (s.e.m.) | 0.4 (±0.1) | 0.7 (±0.1) | 0.1 (±0.1) | 0.7 (±0.7) |
| Systemic Fever| N yes (%) | 4 (5) | 8 (10) | 0 (0) | 0 (0) |
|               | Mean N days (s.e.m.) | 0.1 (±0.03) | 0.2 (±0.06) | - | - |
| Systemic Severity| N +/- (mild) | 9 | 17 | - | - |
|               | N + (moderate) | 3 | 8 | 1 | 1 |
|               | N ++ (severe) | - | 2 | - | - |

Safety of vaccination expressed in various parameters. Severity of adverse events could be graded with - (absent), +/- (mild), + (moderate) and ++ (severe). S.e.m. = standard error of the mean.
Finally, the kinetics of the immune response were similar in both groups with neutralising antibody responses peaking at 4 weeks after vaccination.

Several aspects of this study require comment. First, assuming 99% seroprotection after primary vaccination in both groups, the population size in this study does not allow to detect differences less than 4% between the experimental (i.d.) and conventional (s.c.) vaccination groups. However, the numbers are sufficient to reliably measure a log 0.7 virus neutralising capacity in at least 95% of those vaccinated intradermally, which meets the minimal required percentage of seroprotection after vaccination, as defined by the WHO [20]. Second, the viral dose contained in the trial vaccine was $3.5 \times 10^4$ PFU/0.5mL, which is equivalent to approximately $5 \times 10^3$ Mouse Lethal Dose (MLD)$_{50}$ (21). A fivefold reduction of vaccine dose for i.d. delivery then still contains the minimal potency requirement ($1 \times 10^3$ MLD$_{50}$) as defined by the WHO [20], meaning that the results of this study cannot exclude that s.c. vaccination with 0.1mL dose might be protective. Several lines of evidence however suggest that this may not be the case. More than sixty years ago Fox and colleagues verified the protective efficacy of human serum from vaccinees in a mouse challenge model and observed that at a similar vaccine dose, sera from intradermally injected subjects were more efficacious than sera of those injected subcutaneously [11]. Additionally, 0.1mL s.c. delivery of a live attenuated chimeric flavivirus vaccine against Japanese encephalitis in non-human primates resulted in a 7-fold lower neutralising antibody response compared to 0.1mL i.d. delivery by micro needle [22]. Finally, this study has been performed in healthy adult volunteers who represent travellers to and not individuals living in an area of potential yellow fever transmission. This study should be repeated in a population living in a yellow fever endemic area, to account for differences in skin tissue composition, possible interactions by cross-reactive antibodies against other flaviviruses, and possible decreased immune response due to malnutrition or chronic parasitic infections.

In regard to the reproducibility of these results, the significant variation in viral load between YF-17D vaccine batches is of importance. The batches generally contain 5-50 times the minimal required potency dose to account for possible loss during storage and transportation [5]. The YF-17D batch used in this study contained five times the minimal required potency dose, and is therefore at the low side of the batch-variability in viral vaccine load. Intradermal YF-17D vaccination with other batches will thus yield similar results, as no other batch is likely to contain less virus particles. Correct i.d. vaccination is technically more demanding than subcutaneous or
intramuscular vaccination. By introducing a minimal diameter cutoff of the cutaneous
wheal following i.d. vaccination, we allowed to control for proper i.d. delivery of the
vaccine. To our opinion, this simple test is a valuable tool to ensure correct i.d.
vaccination.

Local adverse events such as erythema and swelling were reported to occur longer in
the i.d. vaccinated group. This is consistent with other intradermally administered
vaccines [7,8], and might represent the inflammatory reaction due to activation of
local immunomodulating cells. To our opinion this increased duration of local adverse
events will not be a reason to renounce the new cost-effective method of yellow fever
vaccination investigated, as they were not experienced as more severely than the
adverse events in the s.c. group. Evidently, adverse events with a frequency beneath
1/77 after low dose i.d. vaccination could not be detected in this study.

The participants who had been previously vaccinated against yellow fever all showed
seroprotection after booster vaccination, irrespective of their pre-booster VN capacity,
implying that circulating neutralising antibodies did not interfere with the induction of a
booster response. Furthermore, this study shows that detectable YF–17D replication as
evidenced by viraemia in the week after vaccination, was not required for induction of a
booster response, which is consistent with previous findings by Reinhardt et al. [23].

The enhanced efficiency of the i.d. route of vaccination may be explained by direct
targeting of antigen presenting cells (APCs) in the dermis and epidermis. Despite the
possibility of YF–17D replication in dendritic cells [24], Palmer and colleagues found
this replication to be restricted due to rapid processing of the virus [25]. Together with
the fact that despite the lower vaccine dose the number of intradermally vaccinated
participants in which viraemia was measured was not reduced, it is likely that an even
more reduced vaccine dose (than fivefold reduction) administered i.d. could induce a
protective immune response.

The findings of this study have the following practical implications: 1) in case of an
outbreak of urban yellow fever or vaccine shortage for travellers to endemic areas, i.d.
administration of yellow fever vaccine will allow immunisation of at least four times as
many individuals as s.c. vaccination with the same limited vaccine supply, 2) provided
that these results can be confirmed in field studies in areas with potential yellow fever
virus transmission, the i.d. vaccination strategy could be implemented in routine
immunisation programmes and support the 'yellow fever risk reduction initiative'
Intradermal yellow fever vaccination

launched by the WHO and UNICEF to envisage the immunisation of 48 million people in 12 high-risk countries between now and 2010 [26], 3) finally, these results suggest that travellers with a possible history of egg allergy in whom an i.d. test dose of 0.1 ml YF–17D vaccine yielded a strong local urticarial reaction do not need further vaccination, but this should always be checked by virus neutralisation tests.
References

1. Robertson SE, Hull BP, Tomori O, Bele O, LeDuc JW, et al. Yellow fever: a decade of reemergence. JAMA 1996; 276: 1157–62.
2. Monath TP. Yellow fever: an update. Lancet Infect Dis 2001; 1: 11–20.
3. WHO Weekly epidemiological record. Yellow fever situation in Africa and South America. http://www.who.int/wer/2006/wer8133.pdf 2005; 81: 317–324. Accessed 10 Oct 2007.
4. Roberts L. Infectious disease. Resurgence of yellow fever in Africa prompts a counterattack. Science 2007; 316: 1109.
5. Monath TP. Yellow Fever. In: Plotkin SA, Orenstein WA, editors. Vaccines. W.B. Saunders Company. 1999 pp. 815–79.
6. Monath TP. Stability of yellow fever vaccine. Dev Biol Stand 1996; 87: 219–25.
7. Belshe RB, Newman FK, Cannon J, Duane C, Treator J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351: 2286–94.
8. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351: 2295–301.
9. Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 1985; 254: 3203–06.
10. Warrell MJ, Warrell DA, Sungtharamai P, Viravan C, Sinsen A, et al. An economical regimen of human diploid cell strain anti-rabies vaccine for post exposure prophylaxis. Lancet 1983; 2:301–4.
11. Fox JP, Luty Kossobudski S, Fonseca da Cunha J. Field studies on the immune response to 17D yellow fever virus. Relation to virus strain, dose and route of inoculation. The American Journal of Hygiene 1943; 38: 113–38.
12. Cannon SA, Dewhurst F. Vaccination by scarification with 17D yellow fever vaccine prepared at Yaba, Lagos, Nigeria. Ann Trop Med Parasitol 1953; 47: 381–93.
13. Dick GW. A preliminary evaluation of the immunizing power of chick-embryo 17D yellow fever vaccine inoculated by scarification. Am J Hyg 1952; 55: 140–53.
14. Center for Disease Control, Mantoux Tuberculosis Skin Test Facilitator Guide. http://www.cdc.gov/tb/pubs/Mantoux/part1.htm (accessed 2nd of August 2007).
15. De Madrid AT, Porterfield JS. A simple micro-culture method for the study of group B arboviruses. Bulletin of the World Health Organization 1969; 40:113–21.
16. Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 1973; 25: 539–44.
17. Nijnuis M, van Maarseveen N, Schuurman R, Verkuilen S, de Vos M, et al. Rapid and sensitive routine detection of all members of the genus enterovirus in different clinical specimens by real-time PCR. J Clin Microbiol 2002; 40: 3666–70.
18. Drosten C, Gottig S, Schilling S, Asper M, Panning M, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 2002; 40: 2323–30.
19. Armitage P, Berry G, Matthews J (2002) Statistical methods in medical research. 4 ed. Oxford: Blackwell Science.
Intradermal yellow fever vaccination

20 World Health Organization Expert Committee on Biological Standardization. 46th report (1998) WHO Technical Report ser. No. 872. Geneva, World Health Organization.
21 Monath TP. Yellow Fever Vaccine. Exp rev vaccines 2005; 4: 553–74.
22 Dean CH, Alarcon JB, Waterston AM, Draper K, Early R, et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax-JE) in non-human primates. Human Vaccin 2005; 1: 106–11.
23 Reinhardt B, Jaspart R, Niedrig M, Kostner C, 'Age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998; 56: 159–67.
24 Barba-Spaeth G, Longman RS, Albert ML, Rice CM. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 2005; 202: 1179–84.
25 Palmer DR, Fernandez S, Bisbing J, Peachman KK, Rao M, et al. Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol 2007; 88: 148–56.
26 WHO (2007) Weekly epidemiological record. Assessment of yellow fever epidemic risk-a decision-making tool for preventive immunization campaigns. http://www.who.int/wer/2007/wer8218.pdf. 82:153–60.
